Effects of bezafibrate therapy on subfractions of plasma low-density lipoprotein and high-density lipoprotein, and on activities of lecithin:cholesterol acyltransferase and cholesteryl ester transfer protein in patients with hyperlipoproteinemia
Homma, Y.; Ozawa, H.; Kobayashi, T.; Yamaguchi, H.; Sakane, H.; Mikami, Y.; Mikami, Y.; Nakamura, H.
Atherosclerosis 106(2): 191-201
1994
ISSN/ISBN: 0021-9150 PMID: 8060379 DOI: 10.1016/0021-9150(94)90124-4
Accession: 002363043
The effects of 12 weeks of bezafibrate treatment on plasma lipoprotein subfraction levels and on activities of lecithin:cholesterol acyltransferase (LCAT) and cholesteryl ester transfer protein (CETP) was investigated in 25 patients with hyperlipoproteinaemia. Bezafibrate reduced plasma levels of VLDL-TC and VLDL-TG by 69 and 66% (P<0.001) and plasma levels of IDL-TC and IDL-TG were decreased by 37 and 31% (P<0.01). Bezafibrate had no significant effects on plasma levels of LDL1 (1.019 < d < 1.045)-TC and LDL1-TG but significantly increased the plasma level of LDL1-TC in the subgroup of 9 patients with type IV hyperlipoproteinaemia.